Deep 6 AI

Pasadena, CA, United States All United States companies → — Founded 2016

Biotech / Drug Discovery Clinical AI Platform

Cardiology Neurology Oncology

Drug Discovery & Research

Acquired — $54.8M

Website Claim this company

Products

Deep 6 AI

Drug Discovery & Research

Deep 6 AI is an AI-powered clinical trial acceleration software that uses natural language processing to mine patient data from Electronic Medical Records (EMRs) and precisely identify eligible patients for clinical trials in minutes, rather than months. It also supports site feasibility and real-world evidence generation.

Enterprise licensing model; not publicly disclosed.

See all 1 product →

About Deep 6 AI

Deep 6 AI is a healthcare artificial intelligence company that specializes in accelerating clinical trials by leveraging advanced AI and Natural Language Processing (NLP) to analyze vast amounts of patient data. For physicians, this means a significantly streamlined process for identifying eligible patients for clinical research studies. The platform delves into both structured data (such as ICD-10 codes, lab values) and, crucially, unstructured data, which constitutes up to 80% of a patient’s medical record, including physician notes, pathology reports, genomics results, and radiology reports.

By transforming fragmented medical documents into unified “patient graphs,” Deep 6 AI’s software can precision-match complex trial inclusion and exclusion criteria to patient characteristics in minutes, rather than the months typically required by manual methods. This capability not only reduces the burden on research staff and lowers screen failure rates but also expands access to cutting-edge investigational treatments for patients. The platform operates within a secure, HIPAA-compliant environment, enabling healthcare organizations to enhance their research capabilities, generate real-world evidence, and ultimately bring life-saving therapies to patients faster.

Focus Areas

Clinical trial acceleration patient recruitment real-world evidence (RWE) generation AI Natural Language Processing (NLP) machine learning precision medicine oncology rare diseases

Business Intelligence

Key Investors	Point72 Ventures, Canaan Partners, AI Venture Labs, Brooks Hill Partners, Cedars-Sinai Accelerator, Healthbox, Iaso Ventures, GSR Ventures
Partnerships	Texas Tech University Health Sciences Center, Graticule, Magnolia Market Access, WCG, Cedars-Sinai Medical Center, Texas Medical Center (TMC), Rutgers University
Acquisitions	Acquired by Tempus on March 11, 2025
Technology	AI-powered, Natural Language Processing (NLP), Machine Learning (ML), analyzes structured and unstructured EMR data (physician notes, pathology reports, genomics results, lab reports), cloud-based (AWS Virtual Private Cloud), patient graphs, Cohort Builder, Trial Recommender, HIPAA-compliant

What Physicians Need to Know

Clinical Trial Acceleration & Patient Recruitment

Deep 6 AI leverages AI and Natural Language Processing (NLP) to analyze both structured and unstructured Electronic Medical Record (EMR) data in real-time, drastically reducing patient identification and recruitment times from months to minutes or days. This addresses the significant bottleneck in clinical trials, enabling faster access to new treatments.

Real-World Evidence (RWE) Generation

The platform facilitates the curation of deeper, real-world data (RWD) sets for prospective monitoring, registries, and RWE studies, providing valuable insights for research and development.

AI, NLP, and Machine Learning Expertise

At its core, Deep 6 AI utilizes advanced Artificial Intelligence, Natural Language Processing, and Machine Learning to mine vast amounts of clinical data, including physician notes, pathology reports, genomics results, and lab reports, which often contain up to 80% of patient data that traditional systems miss.

Precision Medicine & Specialized Areas

The platform is designed to advance precision medicine by identifying highly specific patient cohorts for complex trials, particularly in challenging areas like oncology and rare diseases, where nuanced eligibility criteria are common.

Comprehensive Data Analysis (Structured & Unstructured)

A key specialization is the ability to process and understand both structured data (e.g., ICD-10 codes, lab values) and unstructured data (e.g., free-text physician notes, imaging reports, genomic profiles), creating a holistic patient view.

Physician Tip

For physicians, Deep 6 AI offers a powerful tool to enhance patient care and research participation. You can quickly identify eligible patients for cutting-edge clinical trials, providing them with access to advanced treatments they might not otherwise find. The platform significantly reduces the manual burden of patient screening, allowing you to focus more on patient care. Leverage the 'Trial Recommender' feature to suggest targeted studies to eligible patients during their visits, integrating research seamlessly into clinical workflows. The ability to search unstructured data means even complex patient histories are thoroughly evaluated, increasing the chances of finding suitable trials for hard-to-reach or rare disease patients. Rest assured that patient data is handled with the highest security and HIPAA compliance, with data ownership remaining with your healthcare organization. The recent acquisition by Tempus AI further strengthens its capabilities in precision medicine and broadens its reach to more provider sites.

Deep 6 AI's platform is built for robust integration within healthcare ecosystems. It handles data ingestion from major Electronic Health Record (EHR) systems like Epic and Cerner via secure, normalized pipelines. The platform utilizes a cloud-native solution on AWS Virtual Private Cloud and has enhanced its healthcare data pipeline by implementing the Aidbox FHIR server, ensuring high performance, data quality, and adherence to FHIR standards for interoperability. It also incorporates multiple data sources beyond EMRs, such as genomics, custom databases, cancer registries, and CTMS.

At a glance

Founded 2016

HQ Pasadena, CA, United States · United States

Team size 19

CEO Wout Brusselaers

Funding Acquired — $54.8M

Products 1

Visit site

Products by Deep 6 AI

1 product in the directory

Deep 6 AI

Drug Discovery & Research

Enterprise licensing model; not publicly disclosed.

What the Web Says

Deep 6 AI receives generally positive feedback for its product, particularly in its ability to accelerate patient recruitment for clinical trials through advanced AI and NLP. Users appreciate its efficiency and the quality of insights provided. As an employer, reviews suggest a positive work environment with opportunities for growth, though some common startup challenges like rapid change and occasional workload pressure are mentioned.

Overall: Positive

Strengths

Significantly speeds up patient identification and recruitment for clinical trials.
Powerful AI and NLP capabilities for extracting relevant patient data.
User-friendly interface and intuitive design.
Reduces manual effort and improves accuracy in patient matching.
Positive company culture with supportive colleagues and management.
Meaningful work contributing to medical research.

Limitations

Integration with existing hospital systems can sometimes be complex or time-consuming.
Initial learning curve for new users to fully leverage all features.
Occasional reports of high workload or fast-paced environment common in startups.
Some users desire more customization options for specific research needs.
Pricing information is not always transparently available.
Limited public reviews on certain platforms like Capterra.

Based on reviews from: G2, Glassdoor, Healthcare IT News, Reddit, KLAS Research (indirect mentions/related discussions)

Last updated: 2026-08-21

Videos

News, demos, and interviews about Deep 6 AI.

Loading videos...

Videos load interactively. If none appear, search YouTube for Deep 6 AI →

View all on YouTube

Press & Coverage

Tempus AI, Inc. (NASDAQ: TEM)

Tempus Announces Acquisition of Deep 6 AI

Tempus AI acquired Deep 6 AI in March 2025, integrating Deep 6 AI's precision research platform to accelerate clinical trial recruitment and generate real-world evidence. This acquisition expands Tempus's network and enhances its ability to deploy critical applications for patient care and clinical trials.

2025-03

Signalbase

DEEP 6 AI Secures $2.5M in Funding to Revolutionize Clinical Trial Enrollment

Deep 6 AI successfully raised $2.5 million in a funding round in December 2024 to further enhance its AI and natural language processing platform for streamlining clinical trial patient identification. The funding aims to expand its reach within the clinical research community and accelerate patient access to trials.

2024-12

Clinical Trials Arena

Deep 6 AI, Graticule develop clinical trial recruitment algorithm

Deep 6 AI partnered with Graticule in January 2024 to develop a new AI and NLP-powered algorithm for expediting patient screening and recruitment for clinical trials. This solution aims to reduce the time and burden associated with accessing and analyzing electronic medical record data for trial eligibility.

2024-01

Business Wire

Deep 6 AI Announces Substantial Expansion of its Innovative AI-Based Clinical Trial Acceleration Software and Research Ecosystem

Deep 6 AI announced significant growth in June 2021, expanding its AI-based clinical trial acceleration software and research ecosystem with new customer wins and executive team additions. The platform connects sponsors, CROs, researchers, physicians, and patients to accelerate therapies.

2021-06

Technology Magazine

Deep learning in healthcare: Deep 6 AI and MIT demo uses | Technology Magazine

In May 2020, Deep 6 AI was featured for its use of deep learning and natural language processing to screen patients for clinical trials, especially in the age of precision medicine. Their method processes medical records to identify relevant criteria and has led to over 100,000 matches.

2020-05

Forbes

Startup Deep 6 Lands $17 Million To Use AI To Help Find Patients For Clinical Trials

Deep 6 AI secured $17 million in Series A funding in November 2019, bringing its total funding to $22 million, to advance its AI-powered technology for clinical trial patient recruitment. The technology aims to identify suitable candidates in minutes rather than months by analyzing patient health information across various medical records.

2019-11

Los Angeles Business Journal

Deep 6 AI Raises $17 Million Series A - Los Angeles Business Journal

Deep 6 AI, a Pasadena-based medical software developer, raised a $17 million Series A round led by Point72 Ventures in December 2019. The funding was intended to scale the company's software and expand its market to more hospitals, pharmaceutical companies, and governments.

2019-12

John Snow Labs

Case study Deep6 accelerates clinical trial recruitment with Spark NLP (Deep 6)

Deep 6 AI utilizes advanced data and engineering techniques, including Spark NLP, to significantly accelerate clinical trial recruitment by finding better-matching patients in minutes. This approach addresses the challenge of unstructured patient data in medical histories that traditionally slows down the recruitment process.

unknown

Frequently Asked Questions

How does Deep 6 AI accelerate clinical trial patient recruitment and what role do AI and NLP play?

Deep 6 AI accelerates patient recruitment by leveraging AI and Natural Language Processing (NLP) to analyze both structured and unstructured Electronic Medical Record (EMR) data in real time. This allows for precise matching of complex trial inclusion/exclusion criteria to patient records in minutes, significantly reducing the time traditionally spent on manual chart review.

What specific products or solutions does Deep 6 AI offer for precision medicine, oncology, and rare diseases, and how do they utilize real-world evidence (RWE)?

Deep 6 AI's core offering is the Precision Research Ecosystem, which includes tools like Cohort Builder and Trial Recommender, and a specialized Genomics Module. These solutions enable healthcare organizations to identify highly specific patient cohorts for precision medicine, oncology, and rare disease trials by mining deep clinical and genomic data, and also facilitate the generation of real-world evidence (RWE) for prospective monitoring and studies.

What are Deep 6 AI's compliance and data security measures, particularly concerning patient privacy (e.g., HIPAA)?

Deep 6 AI is fully HIPAA-compliant and operates within a secure cloud environment (AWS Virtual Private Cloud), ensuring robust data security and privacy. The platform incorporates de-identification and security controls, with data ownership always remaining with the healthcare organization.

What is the typical pricing model for Deep 6 AI's platform, and what kind of support and implementation assistance can healthcare organizations expect?

Deep 6 AI operates on an enterprise licensing model, typically involving annual or multi-year contracts, with pricing customized based on deployment scale and services required rather than being publicly disclosed. Healthcare organizations can expect support for integration into existing workflows, user training, and assistance with query building and feasibility assessments.

What is the current company status and stability of Deep 6 AI, including any recent acquisitions or significant partnerships?

Deep 6 AI was acquired by Tempus AI in March 2025, integrating its AI-powered precision research platform into Tempus's broader efforts to advance precision medicine. This acquisition enhances Deep 6 AI's reach and stability, leveraging Tempus's extensive network and resources.

How does Deep 6 AI integrate with existing Electronic Medical Record (EMR) systems, and what types of data can it analyze?

Deep 6 AI integrates with major EMR systems like Epic and Cerner via secure, normalized pipelines. The platform is capable of analyzing both structured data (e.g., ICD-10 codes, lab values) and a significant portion of unstructured data, including physician notes, pathology reports, genomics results, and radiology reports, to create a comprehensive patient profile.

Can Deep 6 AI help with site feasibility and reducing the burden on clinical staff during trial planning?

Yes, Deep 6 AI significantly aids in site feasibility by providing sponsors with real-time, aggregated data on eligible patient populations, de-risking trial planning and site selection. Its features, such as the Cohort Builder and Trial Recommender, reduce the manual burden on site staff and physicians by quickly identifying potential candidates and streamlining the screening process.

Related Companies

Suggest an Edit →